Synlogic

DESIGNED FOR LIFE



November 2019
Corporate Presentation

synlogic

Forward Looking Statements

This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this presentation, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants may identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, the approach we are taking to discover and develop novel therapeutics using synthetic biology; statements regarding the potential of our platform to develop therapeutics to address a wide range of diseases, including: inborn errors of metabolism, inflammatory and immune disorders, and cancer; the future clinical development of Synthetic Biotic medicines; the potential of our technology to treat phenylketonuria; the expected timing of our anticipated clinical trial initiations; the benefit of orphan drug and fast track status; the adequacy of our capital to support our future operations and our ability to successfully initiate and complete clinical trials; the results of our collaborations; and the difficulty in predicting the time and cost of development of our product candidates. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the uncertainties inherent in the preclinical development process; our ability to protect our intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in our filings with the SEC. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in our quarterly report on Form 10-Q filed with the SEC on November 12, 2019, and in any subsequent filings we make with the SEC. The forward-looking statements contained in this presentation reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.

Synthetic Biotic™ Medicines Designed For Life

Harnessing nature and technology
to create LIVING medicines
designed to significantly
improve patients' LIVES

Synthetic Biotic™ Medicines
A Novel Class of Engineered Living Medicines

SYNTHETIC

- Designed genetic circuits to execute biological functions
- Degradation of disease-causing metabolites
- Production of therapeutic molecules

BIOTIC

- Bacterial chassis
- Non-pathogenic
- Amenable to genetic manipulation

PATHWAYS, COMBINATIONS, BIOMARKERS

PROGRAMMABLE POTENCY AND CONTROL

LOCAL ACTIVITY, REDUCED SYSTEMIC TOXICITY



Synthetic Biotic Portfolio: Breadth and Potential

Initial Applications Designed to Target Different Sites of Action in Metabolic and Immunomodulatory Diseases

METABOLIC DISEASES

Rare Metabolic Disease

Broad Metabolic Disease

Small or Large Intestine



"Cold" Solid Tumors

Immuno-Oncology

Small or Large Intestine

Inflammatory and Autoimmune

IMMUNOMODULATION

synlogic

Investing in Development of a Robust Pipeline for a Range of Diseases



Rare Metabolic Diseases

Immunomodulation

synlogic

Metabolic Disease Pipeline

synlogic

SYNB1618 for Phenylketonuria (PKU)

Goal: Managing Plasma Phe Levels

PKU is a rare inherited amino acid metabolism disorder

- Causes build up of amino acid phenylalanine (Phe) in the body
- Today, less than half of adults are at or below target Phe levels of 120-360 µmol / L
- If left untreated, symptoms include cognitive impairment, convulsions, behavioral problems, skin rash

Patients:

- 16,500 diagnosed in US, similar in EU5

Treatment:

- Phenylalanine is found in all proteins therefore low protein diet is followed (no meat, dairy, nuts, eggs)
- KUVAN® (sapropterin dihydrochloride): PAH cofactor. 20-40% of patients are responders
- Palynziq™ (pegvaliase-pqpz): injectable, pegylated, bacterial enzyme (phenylalanine ammonia-lyase or PAL) for treatment of adult patients

Target Profile to Address Unmet Need:

- Manage Phe below target levels to prevent irreversible cognitive damage
- Increase natural protein intake: classic PKU patients' natural protein intake is typically less than 10g
- Oral dosing without systemic toxicity

SYNB1618 Mechanism of Action

Amino acids from dietary proteins
(absorption and recirculation)



Engineered Probiotic Bacteria: *E. coli* Nissle
Components of Synthetic Genetic Circuit



When Phe is not efficiently metabolized (PKU) **SYNB1618** provides an alternative mechanism

- **PAL3**: produces TCA which is converted to HA in the liver and is excreted in urine
- **LAAD**: produces phenylpyruvate (PP)

SYNB1618 Preclinical Characterization

Biomarkers Demonstrate Activity of SYNB1618 in Mouse Model of PKU and Healthy NHPs

nature biotechnology

Development of synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria

Vincent M Isabella et al, Synlogic, Inc.

IN VIVO EFFICACY IN (PKU) PAH$^{enu2/enu2}$ MOUSE







DOSE RESPONSE IN HEALTHY NHPs





Nat. Biotechnol. 2018 Oct;36(9):857-864

synlogic

SYNB1618 Phase 1/2a Study Design



PKU Clinical Trial Design

- Randomized, double-blind placebo-controlled study at multiple sites in the US
- Primary outcome: establish safety/tolerability following single and multiple doses in HV and PKU patients
- Secondary outcome: SYNB1618 kinetics in feces
- Exploratory: change from baseline in plasma and urinary biomarkers of Phe metabolism

SYNB1618 in the Clinic: Safety

Phase 1/2a SAD/MAD Study Demonstrates Safety and Clearance in Healthy Volunteers and PKU Patients

56 healthy volunteers, 14 PKU patients	Received at least one dose of SYNB1618 or placebo	Adults Age range: 18-62 yrs old

- ✓ There were no treatment-related serious adverse events, no systemic toxicity or infections
- ✓ Treatment-emergent adverse events were either mild or moderate in severity, and reversible. Most adverse events were GI-related
- ✓ Single dose MTD in healthy volunteers was defined as $2x10^{11}$ CFU. Doses above this level were associated with dose-limiting GI adverse events
- ✓ Based on pharmacodynamic data and tolerability profile, a dose of $7x10^{10}$ CFU was identified for the second part of the study in PKU patients
- ✓ Dose of $7x10^{10}$ CFU TID over seven days was well-tolerated in PKU patients. There were no discontinuations.
- ✓ All subjects cleared the bacteria (one PKU patient in follow-up). There was no evidence of colonization, and no subject required antibiotics

SYNB1618 in the Clinic: Activity

Statistically Significant and Equivalent Activity of SYNB1618 in Healthy Volunteers and Patients

Protein shake / meal



D5-Phe



SYNB1618 or placebo



Measure over 6hrs:

Plasma:

- **Phe/D5-Phe**
- **TCA/D5-TCA**

Urine: HA/D5-HA

MD URINARY HA AND D5-HA



HA=hippurate, D5-HA= labeled HA,
CFB=change from baseline, CFP=change from placebo
HV=healthy volunteer
PKU=phenylketonuria patient

Key: HA: Hippurate, D5-HA: labeled HA, CFB: change from baseline, CFP: change from placebo

Modeling: Potential For Phe Reduction in PKU Patients



Ranges represent

- Low: PAL mechanism only (conservative)
- High: PAL + LAAD activity (estimates maximum with both pathways)

SYNB1618 Potential to Address Unmet Need Across Patient Groups



synlogic

Development of Lyophilized SYNB1618

- Improved fermentation process enables production of a solid formulation of SYNB1618 with:
  - Minimal impact on cell viability and activity
  - Similar activity to frozen liquid as measured by Phe consumption and biomarker production
  - Improved quality attributes
  - Patient and commercialization-friendly presentation
  - Stability profile at 2-8 °C and room temperature
- Process is robust and reproducible at 30 L production scale
- GMP cleanroom build-out has been completed, and lyophilized SYNB1618 material has been manufactured and released for clinical use
- Bridging study ongoing in healthy volunteers

Batch to Batch Consistency of SYNB1618 Solid Formulation

Viability



Activity in WT mice



synlogic

Stability of SYNB1618 Solid Formulation





Upcoming Milestones and Path Forward

- Established new solid formulation and manufacturing process ✓
- Completed EPO1 interactions with FDA to align on program plans (clinical, manufacturing, toxicology) ✓
- Completed Phase 1/2a study (healthy volunteers and PKU patients) ✓
- Initiate bridging study with solid formulation in Q3 2019 ✓
- Phase 2 study in PKU patients to assess Phe lowering to start in 1H 2020

Immuno-Oncology Pipeline

synlogic

Synlogic Vision for Immuno-Oncology

Expand the Benefits of Immunotherapy Broadly Across Tumor Types

CHECKPOINT INHIBITORS HAVE TREATMENT FAILURES

For indications where immune checkpoint inhibitors are indicated, 55-87% of patients fail to respond

Failure Rates for Select FDA Approved CPI Monotherapy



Other tumors, where CPIs are not indicated, show little-to-no response to checkpoint inhibitors

Bacteria Recognized as Earliest Immunotherapy

"Nature often gives us hints to her profoundest secrets, and it is possible that she has given us a hint in which, if we will but follow, may lead us on to the solution of this difficult problem."

DR. WILLIAM B. COLEY
IMMUNO-ONCOLOGY PIONEER

Enable broad response and remission through engagement of multiple immunomodulatory pathways to enhance tumor inflammation and promote robust T cell responses

synlogic

Dual Innate Immune Activator: Synthetic Biotic Medicine Producing STING Agonist (SYNB1891)

- Synthetic biology applied to confer activities for efficacy and control for safety
- Designed as a dual innate immune activator: combined benefit of bacterial chassis and STING agonist
- The dacA gene is integrated into genome under the control of inducible promoter (P_{fnr}) to produce c-di-AMP (CDA)
- Dual biosafety feature via auxotrophies – no proliferation in tumor, systemic circulation or environment
- Learnings inform future combinations



Auxotrophies

- Diaminopimelic acid (DAP)
- Thymidine

SYNB1891 *In Vitro* Characterization

Interferon Production Across Multiple Human STING Alleles – Activity Greater than Naked STING Agonist

REPORTER HUMAN MONOCYTIC LINE



HUMAN PRIMARY DENDRITIC CELLS



SYNB1891 *In Vivo* Characterization

Dose-dependent Anti-tumor Activity of SYNB1891 Prototype Strain (PT1) as a Single Agent

10^7, $5x10^7$ or 10^8 CFU, i.t. (SYNB1891-PT1)

A20 tumors ~100 mm^3, randomize groups

d1 d4 d7 d18











synlogic

SYNB1891 *In Vivo* Characterization

SYNB1891 Prototype Strain (PT1) Leads to Systemic Anti-tumor Immunity





Dual Innate Immune Activator SYNB1891

Designed to Locally Inflame the TME and Systemically Drive Tumor Antigen-Specific Immunity

PROGRESS TOWARDS THE CLINIC

- Tumor Colonization without Leakage
- Enhanced Activity vs. Naked STING Agonist
- Intracellular Activation of STING and Bacterial-Induced Immune Pathways Within APCs
- Dose-dependent Anti-tumor Activity
- Immunological Memory
- Atezolizumab supply agreement in place
- IND Cleared by FDA and Phase 1 clinical trial open
- Phase 1 monotherapy data expected in 2020

PROMISE OVER OTHER APPROACHES

- STING Agonism in Target Cells that Drive Efficacy
- Sparing Cells Where STING Agonism is Detrimental
- Activation of Multiple Innate Immune Pathways
- Low Systemic Risk



synlogic

A Tumor Can Evade Multiple Critical Aspects of the Cancer-Immunity Cycle



MONOTHERAPIES OFTEN FAIL TO OVERCOME TUMOR EVASION MECHANISMS

Recognized Need to Combine Mechanisms to Broaden the Benefit of Immunotherapy

ENGINEER LIVING SOLUTIONS: SYNTHETIC BIOTIC MEDICINES

Rationally Designed for Combinatorial Effect

Locally Inflame the tumor microenvironment (TME)

Systemically Drive Tumor-Antigen Specific Immunity

In Situ Vaccination: Neo-antigen Priming and Sustained Immune Response

synlogic

Adapted from Chen, Mellman; Immunity 2013

Additional Synthetic Biotic Effectors

VISION: Rational Design to Locally Inflame the TME AND Systemically Drive Tumor-Antigen Specific Immunity

RELIEVE IMMUNOSUPRESSION

- Kyn Consumption
- Ade Consumption
- αPD-1 scFv

PROMOTE TRAFFICKING

- Chassis effect
- CXCL10
- Hyaluronidase



PROMOTE AND SUSTAIN IMMUNE ACTIVATION

- IL-15; IL-12
- Arg Production
- 4-1BBL
- OX40L

PRIME FOR TUMOR-ANTIGEN-SPECIFIC VACCINATION

- Chassis effect
- 5FC→5FU
- STING
- αCD40 scFv/CD40L
- TNFα
- IFNγ
- αCD47 ScFv / Sirpα
- GM-CSF

Broad Ambitions in Immuno-Oncology

Vision: Expand and Exceed the Effect of Cancer Immunotherapies

SYNB1891

DISCOVERY PORTFOLIO

INTRATUMORAL



COMBINATIONS

HARNESS THE MICROBIOME

ORAL

synlogic

Synlogic Internal GMP Manufacturing Capabilities

In-house Process Development and Clinical Manufacturing for Early & Mid-Stage Trials



Platform Collaboration to Accelerate Development of Synlogic's Synthetic Biotic Medicines

synlogic

GINKGO BIOWORKS
THE ORGANISM COMPANY

- Provides access to Ginkgo's industrial scale, high-throughput strain optimization and screening
- Enables screening and identification of higher quality optimized candidates, increasing potential for success
- Delivers novel tools for increased candidate potency
- Includes equity investment at a premium, extending runway through multiple milestones

Builds off validated pilot program initiated in 2017

2019 Progress and Milestones



SYNB1618 in PKU

- ✓ Completed Phase 1/2a study in healthy volunteers and patients, top-line data presented
- ✓ Full data presentation Sept. 2019 (SSIEM)
- ✓ Bridging study ongoing

SYNB1891 in Immuno-Oncology

- ✓ Clinical trial material manufactured and CPI agreement in place
- ✓ Phase 1 clinical trial open
- ➢ Monotherapy data expected in 2020

Platform and Pipeline Development

- ✓ Advance **AbbVie collaboration** establish **Ginkgo collaboration**
- ➢ Advance **preclinical pipeline**

Synthetic Biotic™ Medicines Designed For Life

Harnessing nature and technology
to create LIVING medicines
designed to significantly
improve patients' LIVES

synlogic

301 BINNEY ST., #402, CAMBRIDGE, MA 02142
TEL: 617-401-9975
WEB: WWW.SYNLOGICTX.COM | EMAIL: INFO@SYNLOGICTX.COM